3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
12
Pancreatic Neoplasms
6
Neoplasms
6
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Leukemia, Myeloid, Acute
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Multiple Myeloma
4
Lung Neoplasms
4
Leukemia
4
Colorectal Neoplasms
4
Recurrence
3
Neoplasms, Plasma Cell
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Radiodermatitis
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Melanoma
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Communication
2
Carcinoma, Transitional Cell
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
13
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Docetaxel
6
Axitinib
6
Albumin-Bound Paclitaxel
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Nivolumab
5
Erlotinib Hydrochloride
5
Cyclophosphamide
5
Sorafenib
4
Radiation
4
Irinotecan
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
Standard of Care
×
Clear all
No trials found.